Mounjaro vs Wegovy: Which Weight Loss Injection Wins in 2026?

Mounjaro (tirzepatide) vs Wegovy (semaglutide) is the defining battle in the GLP-1 weight loss space for 2026. Both are blockbuster weekly injections, but they work differently — and the differences in weight loss outcomes are substantial. Here’s the complete breakdown.

Mounjaro vs Wegovy: Quick Comparison

Factor	Mounjaro / Zepbound (Tirzepatide)	Wegovy (Semaglutide 2.4mg)
Manufacturer	Eli Lilly	Novo Nordisk
Mechanism	Dual GIP + GLP-1 receptor agonist	GLP-1 receptor agonist only
FDA approval (obesity)	Zepbound approved Nov 2023	Wegovy approved June 2021
FDA approval (diabetes)	Mounjaro approved May 2022	Ozempic approved Dec 2017
Dosing	2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg	0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Average weight loss	20–22% body weight (SURMOUNT-1)	15–17% body weight (STEP-1)
Cardiovascular indication	Pending (SURPASS-CVOT data expected)	Yes (SELECT trial, 2024)
Sleep apnea indication	Yes (Zepbound, 2024)	No specific indication
Monthly list price	~$1,060 (Zepbound), ~$1,070 (Mounjaro)	~$1,350 (Wegovy), ~$970 (Ozempic)

The Weight Loss Difference: Real and Clinically Meaningful

This is where tirzepatide separates itself from semaglutide. In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 20.9% at 15mg — substantially more than Wegovy’s 14.9% in STEP-1. At the highest doses, a significant proportion of tirzepatide patients lost 25% or more of their body weight, approaching surgical weight loss territory.

Trial	Drug / Dose	Average Weight Loss	% Losing ≥15%
STEP-1	Semaglutide 2.4mg	14.9%	~37%
SURMOUNT-1 (5mg)	Tirzepatide 5mg	15.0%	~38%
SURMOUNT-1 (10mg)	Tirzepatide 10mg	19.5%	~55%
SURMOUNT-1 (15mg)	Tirzepatide 15mg	20.9%	~63%

No head-to-head RCT directly comparing tirzepatide vs semaglutide for obesity has been completed (the SURPASS trials compared them for diabetes). But the SURMOUNT-CVOT vs SELECT data and indirect comparisons consistently favor tirzepatide for weight loss magnitude.

Why Does Tirzepatide Work Better for Weight Loss?

Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism on top of GLP-1. GIP is another incretin hormone that, combined with GLP-1 agonism, appears to have synergistic effects on appetite suppression, fat cell metabolism, and energy expenditure. The dual mechanism produces greater effects than GLP-1 alone, particularly at reducing adiposity.

Cardiovascular Benefits: Semaglutide’s Advantage

For proven cardiovascular risk reduction, semaglutide currently leads. The SELECT trial (2024) is the largest cardiovascular outcomes trial for a weight loss drug ever conducted — showing 20% reduction in MACE (heart attacks, strokes, cardiovascular death) in non-diabetic overweight/obese patients with established CVD. Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) data is still emerging. For patients with established heart disease, semaglutide’s CV track record is a meaningful advantage.

Side Effects: Very Similar

Side Effect	Tirzepatide	Semaglutide
Nausea	Common (17–25%)	Common (15–20%)
Diarrhea	Common	Less common
Constipation	Common	Common
Vomiting	Common (early)	Common (early)
Thyroid warning	Yes (black box)	Yes (black box)
Injection site reactions	Rare	Rare

Cost and Insurance Access

Both drugs are expensive at list price (~$1,000–$1,350/month). Zepbound (tirzepatide for obesity) has been gaining formulary coverage, and Eli Lilly has been aggressive with savings programs including a direct-to-consumer self-pay vial option at lower cost. Wegovy (semaglutide) has been on the market longer and has broader prior authorization experience. Neither is covered by Medicare for obesity, though pending legislation could change this.

Which Should You Choose?

Choose tirzepatide (Mounjaro/Zepbound) if: maximum weight loss is the primary goal, you have sleep apnea with obesity (Zepbound has this indication), or you have type 2 diabetes and want the best glycemic + weight results.

Choose semaglutide (Ozempic/Wegovy) if: you have established cardiovascular disease and want proven CV risk reduction (SELECT trial), semaglutide is better covered by your insurance, or you’ve been on it successfully and don’t have a compelling reason to switch.

Frequently Asked Questions

Is Mounjaro or Wegovy better for weight loss?
Mounjaro/Zepbound (tirzepatide) produces greater average weight loss — 20–22% vs 15–17% for Wegovy. At maximum doses, a majority of tirzepatide patients lose 20%+ of body weight, which is approaching bariatric surgery results.

Can I switch from Wegovy to Mounjaro?
Yes, switching between GLP-1 class medications is common. Typically you’d start tirzepatide at a lower initiating dose and titrate up. Discuss the transition plan with your prescriber, including any overlap period and how to handle insurance.

Is tirzepatide safer than semaglutide?
Both have similar safety profiles. Neither has a clear safety advantage over the other. Semaglutide has longer post-marketing safety data given its earlier approval; tirzepatide’s long-term data is still accumulating.

Are Mounjaro and Wegovy the same class of drug?
Both are injectables used for weight management, but they’re not identical. Wegovy contains semaglutide (GLP-1 agonist only). Mounjaro contains tirzepatide (dual GIP + GLP-1 agonist). The dual mechanism is why tirzepatide tends to produce greater weight loss.